Nicholas Gordon

<p>Two years after the first countries approved the Pfizer/BioNTech COVID vaccine for domestic use, China will finally allow the mRNA vaccine to be used domestically—but there&#8217;s a catch. </p><div class="paywall-selector"></div><div class="paywall">



<p>On Friday, China confirmed in a press briefing that <a href="https://www.fmprc.gov.cn/eng/xwfw_665399/s2510_665401/2511_665403/202212/t20221209_10988054.html">it would let German nationals</a> receive the BioNTech COVID vaccine, which uses mRNA technology, in exchange for German health authorities on Wednesday <a href="https://www.reuters.com/world/europe/germany-allow-sinovac-vaccine-chinese-citizens-only-spiegel-2022-12-07/">approving China&#8217;s Sinovac</a> jab for Chinese nationals living in Germany.</p>



<p>The statement from China’s foreign ministry clarifies an earlier announcement by German Chancellor Olaf Scholz during his trip to Beijing that BioNTech would <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/scholz-secures-agreement-allowing-expats-china-use-biontech-covid-19-vaccine-2022-11-04/">be made available</a> to foreign nationals in China.</p>



<p>But Beijing&#8217;s decision to approve the Pfizer/BioNTech jab for a sliver of China&#8217;s population highlights the country’s uneasy relationship with mRNA vaccines and shots developed overseas as Beijing embarks on an exit from its tough COVID-zero policy, which will likely cause a massive outbreak.</p>



<h2 class="wp-block-heading"><strong>Has China approved mRNA vaccines?</strong></h2>



<p>BioNTech is the first mRNA vaccine—and the first developed overseas—approved for use in mainland China, even if it&#8217;s just available to German nationals living there.&nbsp;</p>



<p>Several Chinese companies are developing mRNA vaccines, but none have made it to final approval. In September, Indonesia—not China—became <a href="https://www.scmp.com/news/china/science/article/3194368/chinas-first-mrna-covid-19-vaccine-approved-use-indonesia">the first country</a> to approve a Chinese-developed mRNA vaccine, from pharmaceutical company Walvax. </p>



<p>Fosun Pharmaceuticals, BioNTech&#8217;s distribution partner for greater China, <a href="https://fortune.com/2021/03/20/biontech-covid-vaccine-china-approval-fosun/">secured 100 million</a> doses for the Chinese market in December 2020. Yet Fosun&#8217;s applications to use its doses in mainland China are <a href="https://fortune.com/2021/12/14/biontech-pfizer-fosun-covid-vaccine-china-approval/">still pending</a>, with no indication of when the mRNA vaccine will be approved for widespread use. (The semiautonomous Chinese city of Hong Kong approved BioNTech for use in its vaccination campaigns.)</p>



<p>China has largely relied on two vaccines, from Sinovac and <a href="https://fortune.com/company/sinopharm/" target="_blank">Sinopharm</a>, in its vaccination campaign. The two vaccines use an inactivated virus to confer immunity. Studies show that the two vaccines are less effective at preventing infection, severe disease, and death than the BioNTech and <a href="https://fortune.com/company/moderna/" target="_blank">Moderna</a> shots, which use mRNA technology. </p>



<p><a href="https://www.scmp.com/news/china/science/article/3191684/chinas-sinovac-test-omicron-targeting-vaccines-chile">Sinovac</a> and <a href="https://news.rthk.hk/rthk/en/component/k2/1650995-20220531.htm">Sinopharm</a> are both developing boosters that specifically target the Omicron variant.</p>



<p>Public health officials have <a href="https://fortune.com/2022/12/02/anthony-fauci-china-covid-vaccines-less-effective-sinovac-sinopharm/">blamed China’s less-effective vaccines</a> for hindering its ability to smoothly change its COVID policy. “The efficacy of the China‑made vaccines are not at the level of the vaccines that have been used in the United States,” Anthony Fauci, the outgoing White House medical adviser, told the<em> Washington Post </em>on Dec. 2.</p>



<h2 class="wp-block-heading"><strong>How many Chinese have been vaccinated?</strong></h2>



<p>The more pressing problem, in Beijing&#8217;s view, is not the effectiveness of its vaccines, but that not enough people are vaccinated. Official data released in early December shows that only 40% of China’s over-80 population has received a booster. Health officials at the time pledged to launch new campaigns to vaccinate China&#8217;s elderly, but now the task is especially urgent.</p>



<p>Beijing announced <a href="https://fortune.com/2022/12/07/china-covid-restrictions-reopening-economy-recovery/">sweeping changes</a> to its COVID rules last Wednesday, including letting mild and asymptomatic cases recover at home and limiting lockdowns to individual floors and buildings, rather than whole neighborhoods. A pivot is likely <a href="https://fortune.com/2022/12/07/china-covid-restrictions-reopening-economy-recovery/">good news for China’s economy</a>, dragged down in November by a record COVID outbreak and widespread lockdowns. Chinese consumer sentiment last month fell to levels not seen since early 2020, the start of the pandemic, according to a <a href="https://www.bloomberg.com/news/articles/2022-12-12/china-consumer-sentiment-fell-near-2020-lows-before-lifted-curbs">survey released Sunday</a> by Morning Consult. </p>



<p>But relaxed measures could lead to a surge in cases across China. One of the country’s top medical advisers predicted last week that as much as 60% of the country <a href="https://fortune.com/2022/12/08/china-ends-covid-zero-exit-wave-new-cases-feng-zijian/">could catch COVID</a> in an initial exit wave.</p>



<p>Chinese officials are now reassuring people that an increase in cases is not a cause for concern. State media quoted Zhong Nanshan, the country’s top medical expert, on Friday as saying that Omicron’s death rate is <a href="https://fortune.com/2022/12/11/china-medical-expert-zhong-nanshan-downplays-covid-risks-lockdowns-restrictions-ease/">comparable to that of influenza</a>. </p></div>

Beijing's uneasy relationship with mRNA vaccines is all the more relevant as it begins to relax COVID restrictions.

China approves Pfizer/BioNTech mRNA COVID vaccine—only for foreigners

Woman gets a COVID vaccination in Guizhou province, China

<p>Our new weekly Impact Report newsletter examines how ESG news and trends are shaping the roles and responsibilities of today's executives. <a href="https://mynewsletters.fortune.com/impact-report">Subscribe here</a>.</p>


F-BreakingNews

China

Beijing's uneasy relationship with mRNA vaccines is more relevant as it relaxes COVID restrictions.

China finally approves an mRNA COVID vaccine—but only for some foreigners

China approves Pfizer/BioNTech mRNA COVID vaccine—only for foreigners | Fortune

Carter Johnson

George Lei

Anya Andrianova

Bloomberg

Dollar’s Trump-fueled gains face a reality check late next year

/2024/12/15/dollar-outlook-2025-trump-tariffs-fed-rate-cuts-economy/

Ailbhe Rea

Ellen Milligan

UK, Australia to recommit to defense pact at meeting in London

/2024/12/15/aukus-nuclear-submarine-deal-uk-australia-us-defense-pact-meeting/

Jana Randow

Martin Ademmer

Germany is unraveling just when Europe needs it most

/2024/12/15/german-economy-stagnation-europe-economic-growth-outlook-eurozone/

Bianca Vázquez Toness

Dave Collins

The Associated Press

Recently declassified radio wave technology should be used on drones and operators, Schumer says

/2024/12/15/declassified-radio-wave-technology-drones-operators-identities-chuck-schumer/

Jason Ma

Putin is desperately trying to reverse Russia’s population crisis and sees Ukraine as a solution, experts say

/2024/12/15/russia-population-crisis-vladimir-putin-ukraine-invasion-demographic-trends/

Work trends like AI are forcing Asian professionals to adapt, and fast: ‘The pace of change is speeding up’

/asia/2024/12/15/ai-forcing-asian-professionals-to-adapt-linkedin-coo-dan-shapero/

Paolo Confino

Elon Musk’s lawyer said the SEC demanded the Tesla CEO pay a fine or face charges to resolve an investigation into his purchase of Twitter

https://fortune.com/2024/12/14/elon-musks-lawyer-said-the-sec-demanded-the-tesla-ceo-pay-a-fine-or-face-charges-to-resolve-an-investigation-into-his-purchase-of-twitter/?itm_source=parsely-api

Chloe Berger

Skechers draw backlash for full-page ad in Vogue that reeks of AI. 'You actually didn’t save any money because now I hate you'

https://fortune.com/2024/12/14/skechers-draw-backlash-for-full-page-ad-in-vogue-that-reeks-of-ai-you-actually-didnt-save-any-money-because-now-i-hate-you/?itm_source=parsely-api

Sasha Rogelberg

Return-to-office mandates are associated with an exodus of high performers, research finds

https://fortune.com/2024/12/11/return-to-office-mandate-employees-study/?itm_source=parsely-api

Ani Freedman

Study confirms link between cancer and at least 10 popular ultra-processed foods

https://fortune.com/well/article/ultra-processed-foods-link-cancer-inflammation/?itm_source=parsely-api

Fortune Editors

CEOs struggle to process their new reality after the public glee at Brian Thompson’s killing

https://fortune.com/2024/12/14/unitedhealthcare-killing-ceos-respond-social-media-backlash/?itm_source=parsely-api

Amazon founder Jeff Bezos kept his base salary modest during his 20 years as CEO. It likely saved him millions in taxes

https://fortune.com/2024/12/11/amazon-ceo-founder-jeff-bezos-salary-80000-avoided-taxes/?itm_source=parsely-api